Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients by Paul J. Hengeveld, Joyce Schilperoord-Vermeulen, P. Martijn Kolijn, Julie M. N. Dubois, Peter E. Westerweel, Sabina Kersting, Arnon P. Kater, Mark-David Levin, Anton W. Langerak

Get full text

Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020 by Lina van derStraten, Mark‐David Levin, Manette A. W. Dinnessen, Otto Visser, Eduardus F. M. Posthuma, Jeanette K. Doorduijn, Anton W. Langerak, Arnon P. Kater, Avinash G. Dinmohamed

Get full text

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial by Carsten U. Niemann, Julie Dubois, Kazem Nasserinejad, Caspar da Cunha-Bang, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H.M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Johan A. Dobber, Christian B. Poulsen, Wida Razawy, René Hollestein, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa T. T. Tran, Arnon P. Kater, Mark-David Levin

Get full text